Home PR Newswire
Tuesday, April 21, 2026
23.5
C
Bengaluru
Hot topics
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Not Digital Solutions alone, but Business Solutions that add Value to Customers delivered via Digital Platforms
Yesterday I received a WhatsApp from a famous shoe...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
Hot topics
Indian Pharma November Sales: What Do They Say?
IQVIA's Market Feedback Report (MFR) and PharmaTrac's Acquaint report...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Define and Measure Digital – KPIs and ROI
Measurement and optimization for digital marketing is one of...
From VUCA to TACO: Thriving in a Chaotic World
From VUCA to TACO: Thriving in a Chaotic World
Leaders...
Sales View – On-the-Go Information, Insights & Learning for Pharma Professionals
Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance (IPA)...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Newsletter
Get important news delivered directly to your inbox and stay connected!